Extended Data Fig. 7: Clinical correlates of adipsin.

(a) In cross-section multivariable analyses, higher adipsin levels associate with lower odds of diabetes (OR 0.69) and with higher odds of obesity (OR 1.68). Adipsin is associated with a number of clinical traits including BMI, waist circumference, diastolic blood pressure reduction and reduced HDL cholesterol. Additionally, higher levels associate with significantly lower fasting glucose, with a trend toward improved insulin resistance as measured by HOMA-IR that did not meet the Bonferroni-corrected p-value threshold for significance. Analyses were multivariable linear (t statistic) or logistic regression models (Wald Chi-square test) with two-sided p-values deemed significant at a Bonferroni-corrected p-value threshold of p = 0.05/10 primary traits = 0.005. Similar results were obtained in secondary analyses stratified by Framingham cohort (Offspring vs. Third Generation). (b) Cross-sectional radiographic anatomically specific adiposity volumes were obtained from participants of the Third-Generation Framingham cohort (n = 3068, 2002 to 2005). In secondary analyses, volumetric measures of adiposity reveal that adipsin is strongly associated with subcutaneous (SAT) and intrathoracic adipose volumes and not visceral adipose volumes. With regard to subcutaneous adipose, a one standard deviation rise in adipsin was associated with a 0.4 standard deviation increase in subcutaneous adipose volume. Analyses were multivariable linear regression models (t statistic) with two-sided p-values deemed significant at a p-value threshold of p = 0.05.